Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × eribulin × Lymphoid × Clear all

Phase

Status

Sponsor Class

OTHER 1 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 52 Tumor-Agnostic 9 Sarcoma 8 Thoracic 4 Genitourinary 4 Other solid neoplasm 2 Gastrointestinal 2 Lymphoid 1 Gynecologic 1 Dermatologic 1 CNS 1

Conditions

Neoplasms 1 Lymphoma 1

Interventions

Rituximab 334 Cyclophosphamide 164 obinutuzumab 93 Bendamustine Hydrochloride 92 Vincristine 85 fludarabine 82 Doxorubicin 82 Prednisone 81 venetoclax 78 ibrutinib 77 Lenalidomide 72 Gemcitabine 55 acalabrutinib 42 zanubrutinib 38 Brentuximab Vedotin 38 pembrolizumab 37 Dexamethasone 35 idelalisib 34 ofatumumab 30 Oxaliplatin 28 Chlorambucil 27 polatuzumab vedotin 23 Azacitidine 23 blinatumomab 22 tocilizumab 20 tisagenlecleucel 20 Prednisolone 20 Injections 20 ublituximab 19 tafasitamab 19

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02171260 2019-01-15

BOLD 113

Eisai Inc.

Phase 1 Completed

23 enrolled 22 charts

Lymphoma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡